Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to $39.7 million.

  • Relay Therapeutics' Cash from Investing Activities rose 131.49% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.3 million, marking a year-over-year increase of 1891.16%. This contributed to the annual value of -$41.1 million for FY2024, which is 115.95% down from last year.
  • Latest data reveals that Relay Therapeutics reported Cash from Investing Activities of $39.7 million as of Q3 2025, which was down 47.14% from $75.1 million recorded in Q2 2025.
  • Relay Therapeutics' 5-year Cash from Investing Activities high stood at $75.3 million for Q1 2023, and its period low was -$292.7 million during Q4 2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was $45.5 million (2024), whereas its average is $34.0 million.
  • Per our database at Business Quant, Relay Therapeutics' Cash from Investing Activities tumbled by 563.80% in 2021 and then skyrocketed by 303.24% in 2025.
  • Quarterly analysis of 5 years shows Relay Therapeutics' Cash from Investing Activities stood at -$292.7 million in 2021, then spiked by 49.81% to -$146.9 million in 2022, then skyrocketed by 140.61% to $59.7 million in 2023, then tumbled by 51.41% to $29.0 million in 2024, then spiked by 131.49% to $39.7 million in 2025.
  • Its last three reported values are $39.7 million in Q3 2025, $75.1 million for Q2 2025, and $42.5 million during Q1 2025.